MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Makes Elisrasib's ASCO 2026 Data So Significant

9 hours ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Makes Akeso's ASCO 2026 Plenary Session So Crucial

5 days ago

Why is MBX Biosciences' new CBO appointment so significant for investors

3 weeks ago

What Makes The Hartford's Dividend So Attractive for Income Investors

1 week ago

What is Seaport Therapeutics and Why is its IPO Significant

1 months ago

D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC

D3 Bio reported first-line clinical data for its next-generation KRAS G12C inhibitor, elisrasib (D3S-001), at the ASCO 2026 conference. The study highlights landmark efficacy results for the drug in p...

Stock News•5 days ago

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting

Genprex reported positive clinical data for Reqorsa® gene therapy at the 2026 ASCO meeting, identifying Trop-2 and PTEN biomarkers that correlate with longer progression-free survival in non-small cel...

GNPX

Stock News•1 months ago

Elicio Therapeutics: Hoping To Capitalize On Massive KRAS Hype, But Time Is Running Out

Elicio Therapeutics faces a critical 2026 as it approaches a pivotal KRAS peptide vaccine trial readout. While the data could serve as a significant catalyst for the company, ongoing concerns regardin...

ELTX

Stock News•1 months ago

Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript

Erasca, Inc. (ERAS) released preliminary Phase I data for its pan-RAS molecular glue, ERAS-0015. The company highlighted the drug's potential differentiation within the competitive RAS-inhibitor lands...

ERAS